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OBJECTIVE: The potential influence of magnesium on exercise performance is a subject of increasing interest.
Magnesium has been shown to have bronchodilatatory properties in asthma and chronic obstructive pulmonary
disease patients. The aim of this study was to investigate the effects of acute magnesium IV loading on the aerobic
exercise performance of stable chronic obstructive pulmonary disease patients.
METHODS: Twenty male chronic obstructive pulmonary disease patients (66.2¡8.3 years old, FEV1: 49.3¡19.8%)
received an IV infusion of 2 g of either magnesium sulfate or saline on two randomly assigned occasions
approximately two days apart. Spirometry was performed both before and 45 minutes after the infusions. A
symptom-limited incremental maximal cardiopulmonary test was performed on a cycle ergometer at approximately
100 minutes after the end of the infusion. ClinicalTrials.gov: NCT00500864
RESULTS: Magnesium infusion was associated with significant reductions in the functional residual capacity (-0.41 l)
and residual volume (-0.47 l), the mean arterial blood pressure (-5.6 mmHg) and the cardiac double product (-
734.8 mmHg.bpm) at rest. Magnesium treatment led to significant increases in the maximal load reached (+8 w) and
the respiratory exchange ratio (0.06) at peak exercise. The subgroup of patients who showed increases in the work
load equal to or greater than 5 w also exhibited significantly greater improvements in inspiratory capacity (0.29 l).
CONCLUSIONS: The acute IV loading of magnesium promotes a reduction in static lung hyperinflation and improves
the exercise performance in stable chronic obstructive pulmonary disease patients. Improvements in respiratory
mechanics appear to be responsible for the latter finding.
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INTRODUCTION
Magnesium (Mg) is involved in a great number of
enzymatic reactions and may be involved in several
biological processes, such as energy production, glycogen
catabolism, control of neuronal activity, cardiac electric
conduction, muscular contraction, vasomotor tone, and
blood pressure (1,2). An increased interest in the potential
influence of Mg on exercise performance has been observed
in recent years (2-6).
Nutritional status is an important determinant of exercise
performance in patients with chronic respiratory diseases
(7). A potential role for Mg supplementation in regard to
physical performance may be pronounced in these patients.
Dietary Mg intake has been shown to be related to lung
function, airway reactivity, and respiratory symptoms (8,9).
Some studies have suggested that patients with chronic
obstructive pulmonary disease (COPD) may exhibit
decreased body levels of Mg (10-12). This abnormality
may be related to the chronic use of medicines such as
steroids and bronchodilators or the presence of food in-
gestion disorders. Inhaled Mg and IV Mg administration
have been shown to promote bronchodilation and to
improve lung function in asthmatic subjects (13-15). The
IV administration of Mg during episodes of acute exacer-
bation of COPD in patients treated with albuterol leads to
improvements in the peak flow (12). In another study, also
involving COPD subjects with exacerbations, the effects of
IV Mg were evident only after albuterol inhalation (16).
In a previous study, we have investigated the acute effects
of the IV loading of Mg on the pulmonary function
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parameters of stable COPD patients (17). The treatment was
associated with a reduction in lung hyperinflation and an
improvement in respiratory muscle strength. The objective
of the present paper is to report the effects of acute Mg IV
loading on the exercise performance of stable COPD
subjects. We hypothesized that these patients would have
a high frequency of hypomagnesemia and that Mg treat-
ment would lead to improvements in their maximal exercise
performance, primarily in the most stable subjects with low
Mg levels.
MATERIALS AND METHODS
Patients
All patients had a diagnosis of COPD according to the
Global Initiative for Chronic Obstructive Lung Disease
criteria (18). All individuals were former smokers who
had quit smoking for at least 12 months. They also had been
in a stable clinical condition for at least two months before
admission to the study. Patients with a history of asthma or
allergy, renal failure, heart failure, arrhythmias or cardiac
electrical disturbances, or a significant disease other than
COPD, were excluded. Individuals on chronic oral steroids,
diuretics, or multimineral supplements were also excluded.
The study was approved by the institutional medical ethics
committee, and all of the volunteers gave their written
informed consent at the initial visit. The protocol has also
been registered at ClinicalTrials.gov (NCT00500864). The
pulmonary function data from 18 of the present patients
have been included in a previously published paper related
exclusively to the evaluation of Mg effects on spirometric
parameters and respiratory muscle strength (17).
Study design
This was a randomized, double-blinded, placebo-con-
trolled crossover study. The patients attended an initial visit
during which a clinical history was provided, pulmonary
function tests were performed, basal arterial blood gases
were determined, and blood for the Mg measurements was
obtained. The volunteers were then randomized by drawing
lots to receive one of two sequences of treatment: a placebo
on day 1 and Mg on day 2, or Mg on day 1 and a placebo on
day 2. Although we attempted to keep a fixed interval of
two days between day 1 and day 2, the personal issues of
some subjects led to the extension of this interval up to five
days. The placebo or the Mg was administered slowly by an
IV infusion through venous access in the arm. A total of
33 ml of a 20% Mg sulfate aqueous solution (Aster,
Sorocaba, Brazil) was diluted in 67 ml of saline, correspond-
ing to 2 g of the salt. This dose was given to the patients
based on the recommendations in previously published
papers (19). The placebo was similarly administered as
100 ml of saline. All researchers and technicians were
blinded to the treatment administered, except for the
pharmacist who prepared the solution immediately before
the tests.
On the study days, the patients were subjected to the
following procedures: (i) pulmonary function tests; (ii) an IV
infusion of Mg or the placebo; (iii) blood venous sampling for
plasma Mg measurements 30 minutes after the end of the
infusion; (iv) a new set of pulmonary function tests
performed 45 minutes after the end of the infusion; and v)
a symptom-limited maximal cardiopulmonary exercise test
performed within 90 and 120 minutes after the end of the IV
infusion. All physiological and biochemical measurements
were performed in the morning, with the patients abstaining
from the use of bronchodilators and anti-inflammatory or
any other type of medication for at least 18 hours prior to the
experimental procedures.
Pulmonary function tests
Spirometry data were obtained using a water-sealed Godard
spirometer (SensorMedics, Bilthoven, The Netherlands). The
forced vital capacity (FVC), forced expiratory volume in the
first second (FEV1) and the forced expiratory flow at 25–75% of
the expiratory curve (FEF25–75%) were calculated employing
representative curves. The total lung capacity (TLC) and
residual volume (RV) were measured using the helium
dilution technique. The procedures were performed according
to the American Thoracic Society’s recommendations, and the
predicted normal values were based on Crapo et al. (20-22).
Exercise test
Symptom-limited incremental maximal cardiopulmonary
exercise tests were performed in a cycle ergometer (Corival
400, Lode, Holland) according to the Brazilian Cardiology
Society guidelines (23). All patients were submitted to a ramp
protocol comprising one resting minute, four minutes biking at
no load, and computer-driven automatic load increments every
minute after that. The ramp increments were set in an
individualized way, according to clinical estimates of the
subject’s exercise capacity. The exercise protocols were planned
for test durations between 8 and 12 minutes. The patients were
encouraged to maintain a velocity of 60 rpm, and the same
protocol was applied on both occasions. The heart rate and
rhythm were continuously monitored by an electrocardiogram
and an analogic polygraph (HP 7754A, Palo Alto, CA, USA).
Breath-by-breath respiratory measurements were registered
using an ergospirometer (CPX/D MedGraphics, St. Paul,
Minnesota). The arterial oxygen saturation was continuously
monitored by a pulse oximeter (Moriya 1001, Japan). The
arterial blood pressure was non-invasively measured at two-
minute intervals. The perceptions of dyspnea and leg effort
were measured at the end of the tests, using the modified Borg
scale.
Magnesium levels
Basal plasma magnesium levels were measured in the
venous blood samples collected into lithium-heparin tubes
during an initial visit. Blood samples were also obtained
from the arm that had not received the IV infusions on the
two protocol days. The samples were stored at –80 C˚ after
processing, and all analyses were performed on the same
occasion using a Perkin Elmer model 3110 atomic absorp-
tion spectrometer (Waltham, MA, USA).
Statistical analysis
The data are reported as the means and the standard
deviations. The data obtained on days 1 and 2 were
compared according to the recommended methodology for
investigations with a crossover design, including an assess-
ment for period effects and treatment/period interactions
(24,25). Paired t-tests were employed in this setting. Post hoc
comparisons between the variables with the patients classi-
fied according to the degree of their response to the Mg
infusion were performed employing non-paired t-tests. A p-
value #0.05 was considered to be statistically significant.
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RESULTS
A total of 34 COPD patients were screened, 14 of whom
were not admitted to the study due to the exclusion criteria.
Twenty male patients were enrolled in the study (Table 1).
According to the GOLD standards, nine (45%) patients were
classified as having severe disease, seven (35%) were
classified as having moderate disease, three (15%) were
classified as having very severe disease, and one (5%) was
classified as having mild disease. The mean plasma Mg
level in the basal condition was within the normal range of
the method for the whole group. However, when we
analyzed the results considering the lower level of normal-
ity (1.5 Meq/L) as a limit, seven (35%) of the patients may
be classified as exhibiting an Mg deficiency.
The mean time interval between the first and the second
visit was 1.9 days, ranging from 1 to 5 days. Half of the
volunteers received a placebo on day 1 and Mg on day 2. The
statistical analysis showed no carryover effects, indicating
that the order of the treatments and the variable washout
period did not influence the final results. As expected, the
infusion of 2 g of magnesium sulfate was associated with a
significant increase in the mean plasma ion level compared
with the placebo (Figure 1). The patients did not complain of
serious side effects either during or immediately following
the Mg infusion. Three (15%) patients noted a transitory hot
wave sensation throughout their bodies. Another two (10%)
patients described a short period of drowsiness.
The administration of Mg was not associated with
significant changes in FVC, FEV1, FEV1/FVC or FEF25–75%
(Table 2). Magnesium infusion was associated with a non-
significant decrease in TLC, but it was associated with
significant reductions in the residual volume (RV) and
functional residual capacity (FRC). The mean effects of the
Mg treatment on the TLC, RV and FRC were, respectively,
-0.30 l, -0.47 l, and -0.41 l. The inspiratory capacity (IC)
improved to approximately 0.12 l, but this change did not
reach statistical significance.
Among the several cardiorespiratory parameters measured
with the patients seated on the cycle ergometer at rest,
administration of Mg led to significant decreases only in the
diastolic and mean arterial blood pressures (Table 3). In
addition, the cardiac double product was significantly reduced
as a result of Mg administration (-734.8 bpm.mmHg), and the
arterial oxygen saturation evaluated by the pulse oximeter
improved slightly (0.8%).
The use of Mg was associated with a significant increase
in the duration of exercise (53 seconds) and of the maximal
reached load (8.0 w) (Table 4). The respiratory exchange
ratio (RER) showed a small but significant increase after Mg
administration (0.06). Although Mg use led to a significant
increase in the tidal volume at the peak of exercise (90.2 ml),
there were no differences between the drug and the placebo
treatments regarding the maximal ventilation.
The anaerobic threshold could be determined in only 12
subjects due to technical questions. There were no sig-
nificant differences between the treatment and the placebo
days, except that the time required to reach the anaerobic
threshold after the Mg administration was significantly
longer than that observed after the placebo was adminis-
tered (10923’’ ¡2914’’69943’’ ¡1951’’; p= 0.029). The mean
load reached at the anaerobic threshold was higher after the
Mg administration than after the saline was administered,
but the difference did not reach statistical significance
(52.9¡19.0 w646.6¡19.7 w; p= 0.083).
To clarify the potential mechanisms related to the exercise
improvements after Mg loading, we also analyzed the
results with the patients divided in two subgroups based on
changes in the maximal workloads that were lower than, or
equal to or higher than 5 watts, respectively designated as
Group I and Group II (Table 5). Ten patients were included
in each group, and they did not differ in regard to age
(64.9¡9.6667.5¡7.0 years; p= 0.499) or basal Mg plasma
levels (1.6¡0.461.6¡0.3 mEq/l; p= 0.709). These groups
did not significantly differ regarding the treatment’s effect
on the Mg plasma levels or on the exercise hemodynamic
parameters. However, the Group II patients showed a
significantly better response of IC at rest and of the minute
ventilation at the exercise peak.
DISCUSSION
This study detected low plasma Mg levels in 35% of a
highly selective sample of COPD patients. This figure is
consistent with the results of previous papers (10,11).
Table 1 - Characteristics of the 20 studied male COPD
patients*.
Age (years) 66.2¡8.3
TLC (% predicted) 121.4¡17.9
FVC (% predicted) 89.0¡22.7
FEV1(% predicted) 49.3¡19.8
FEV1/FVC 43.8¡11.4
FEF25-75% (% predicted) 17.0¡9.6
RV (% predicted) 169.7¡52.6
FVC bd. response
(% baseline)
7.7¡8.0
FEV1 bd. response
(% baseline)
9.0¡7.3
FEF25-75% bd. response
(% baseline)
13.9¡18.6
pH 7.42¡0.03
PaO2
(mmHg)
76.3¡7.8
PaCO2
(mmHg)
40.3¡3.9
P(A-a)O2
(mmHg)
21.9¡6.7
Plasma Mg level
(mEq/l)
1.6¡0.4
*TLC: total lung capacity; FVC: forced vital capacity; FEV1: forced
expiratory volume in the first second; FEF25-75%: middle curve forced
expiratory flow; P(A-a)O2: alveolo-arterial oxygen gradient.
Figure 1 - Mg plasma levels after infusion of 2 g of magnesium
sulfate or saline in 20 male COPD patients.
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Most important, this study also demonstrated that acute
IV loading with 2 g of Mg sulfate attenuates static
hyperinflation and positively affects the maximal exercise
performance in stable COPD patients. We chose to
investigate the effects of Mg on exercise performance
following acute IV loading to guarantee similar stable
clinical conditions for the COPD patients on both study
days. Although the experimental conditions do not neces-
sarily replicate results that would be obtained with the
dietary supplementation of Mg for longer periods, they
suggest that elevations in the body’s Mg levels may be
associated with meaningful physiological effects for COPD.
Static hyperinflation in COPD results mainly from the
decreased elasticity of the lung parenchyma associated with
emphysematous changes (26). In this study, treatment with
Mg was associated with significant changes in the FRC and
RV, indicating its substantial effect on lung hyperinflation
approximately 45 minutes after the end of infusion. The
decreases in the FRC and the RV are, most likely, secondary
to the reductions in the expiratory airflow resistance
because there is evidence that Mg antagonizes the action
of calcium at the bronchial smooth muscle level, promoting
relaxation and bronchodilatation (27). Other potential
mechanisms leading to bronchodilatation may also include
the inhibition of the release of acetylcholine at the nerve
endings, stimulation of prostacyclin generation, and
increases in the local synthesis of nitric oxide (28-30).
The Mg loading also led to significant changes in the
cardiovascular parameters at rest. The mean blood pressure
dropped approximately 5.6 mmHg, and this effect was
secondary to a significant decrease of the diastolic measure-
ment. The latter finding suggests that Mg-promoted
peripheral arteriolar dilatation and the reduction of the
systemic peripheral resistance are the most important
mechanisms responsible for the decrease in the mean
arterial blood pressure (31). The significant effect on the
group’s mean double product following Mg use indicates
that the treatment was responsible for a reduction in the
heart’s work and in the level of myocardial oxygen
consumption at rest.
A small but significant increase in SaO2 has also been
found at rest following Mg administration. Although this
finding could actually represent an improvement in gas
exchange, an alternative explanation may be found in the
vasodilatory effect of Mg itself. Because pulse oximeters
evaluate SaO2 based on changes in skin color, improve-
ments in peripheral perfusion associated with vasodilata-
tion may lead to overestimated readings (32).
The most striking finding observed in the incremental
maximal exercise test was the significant improvement in
Table 2 - Effects of Mg loading on the pulmonary function parameters of 20 COPD patients*.
Saline Mg
Treatment effect (CI
95%) (Mg-Saline) p-value
Before After Before - After Before After Before - After
TLC (l) 6.35¡1.16 6.47¡0.95 0.12¡0.80 6.19¡0.85 6.01¡1.04 -0.18¡0.90 -0.30 (-0.73 – 0.13) 0.161
FVC (l) 2.85¡0.80 2.88¡0.88 0.03¡0.24 3.11¡0.72 3.18¡0.80 0.07¡0.19 0.03 (-0.08 – 0.14) 0.542
FEV1 (l) 1.27¡0.56 1.26¡0.61 -0.01¡0.10 1.28¡0.53 1.31¡0.56 0.03¡0.13 0.04 (-0.03 – 0.11) 0.227
FEV1/FVC (%) 43.4¡10.4 42.4¡11.1 -0.95¡3.21 42.4¡10.5 42.7¡9.9 0.29¡3.41 1.24 (-0.88 – 3.36) 0.235
FEF25-75% (l) 0.44¡0.27 0.40¡0.22 -0.03¡0.11 0.43¡0.24 0.43¡0.24 -0.01¡0.10 0.03 (-0.04 – 0.09) 0.370
FRC (l) 4.34¡1.07 4.38¡0.83 0.04¡0.84 4.12¡0.83 3.75¡1.01 -0.37¡0.93 -0.41 (-0.82 – -0.01) 0.048
RV (l) 3.40¡1.03 3.54¡0.99 0.13¡0.83 3.21¡0.69 2.87¡0.92 -0.34¡0.97 -0.47 (-0.92 – -0.02) 0.042
ERV (l) 0.94¡0.58 0.85¡0.56 -0.09¡0.23 1.02¡0.72 0.87¡0.50 -0.14¡0.51 -0.05 (-0.29 – 0.19) 0.677
IC (l) 1.98¡0.49 2.07¡0.56 0.09¡0.31 2.05¡0.43 2.25¡0.48 0.20¡0.27 0.12 (-0.05 – 0.28) 0.148
*TLC: total lung capacity; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; FEF25-75%: middle curve forced expiratory flow; FRC:
functional residual capacity; ERV: expiratory reserve volume; IC: inspiratory capacity.
Table 3 - Effects of Mg loading on the cardiorespiratory parameters of 20 COPD patients at rest*.
Saline Mg
Treatment Effect (CI 95%)
(Mg-Saline) p-value
HR (bpm) 74.6¡11.2 72.8¡9.8 -1.8 (-5.4 – 1.8) 0.308
SBP (mmHg) 137.8¡25.5 131.0¡17.1 -6.8 (-15.6 – 2.1) 0.127
DBP (mmHg) 87.5¡13.3 82.5¡8.7 -5.0 (-9.2 – -0.8) 0.023
MBP (mmHg) 104.3¡15.6 98.7¡10.5 -5.6 (-10.2 – -1.0) 0.019
SaO2 (%) 95.2¡2.3 95.9¡2.0 0.8 (0.01 – 1.49) 0.048
Double product (bpm.mmHg) 10,261.3¡2,291.9 9,526.5¡1,638.5 -734.8
(-1,362.6 – -106.2)
0.024
RR (bpm) 19.0¡5.4 19.3¡3.7 0.3 (-2.1 – 2.7) 0.794
TV (ml) 517.0¡150.7 575.4¡222.4 58.4 (-62.8 – 179.5) 0.326
MV (l/min) 9.7¡3.6 9.3¡2.4 -0.4 (-2.0 – 1.2) 0.608
VO2 (ml/min) 204.2¡82.5 202.2¡78 -2.0 (-46.9 – 43.0) 0.929
VCO2 (ml/min) 167.6¡66.4 167.5¡67.2 -0.1 (-39.5 – 39.3) 0.996
RER 0.83¡0.14 0.83¡0.10 -0.01 (-0.072 – 0.062) 0.877
PETO2 (mmHg) 101.9¡5.4 100.9¡4.9 -1.0 (-2.73 – 0.73) 0.240
PETCO2 (mmHg) 30.1¡4.2 30.2¡3.1 0.05 (-1.14 – 1.24) 0.931
*HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean arterial blood pressure; SaO2: peripheral arterial oxygen saturation;
RR: respiratory rate; TV: tidal volume; MV: minute ventilation; VO2: oxygen consumption; VCO2: carbon dioxide production;
RER: respiratory exchange rate; PETO2: end tidal expiratory oxygen; PETCO2: end tidal expiratory carbon dioxide.
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the maximal achieved load associated with Mg treatment.
This occurred although there were no significant differences
in the peak oxygen consumption, or in Borg dyspnea and
the leg fatigue scores, between treatment days. These results
indicate that the overall exercise performance improved
after Mg loading, as more work was performed with the
same amount of VO2 and corresponding levels of limiting
symptoms. The cardiovascular measurements evaluated at
the maximal exercise load also did not show significant
changes with Mg treatment. Although the tidal volume
measured at the peak of exercise was significantly higher
after Mg administration, the observed elevation in peak
ventilation did not reach statistical significance (p= 0.078).
To further explore the potential mechanisms related to the
improvement of exercise performance, we have compared
the effects of the Mg treatment on the measurements of two
sub-sets of patients, classified according to the level of work
load responses. Neither basal Mg plasma levels, nor the
degree of Mg plasma elevations after loading, differed
between the groups. Additionally, there were no significant
differences in the hemodynamic parameters during exer-
cise. Both groups also exhibited decreases of similar
proportions in TLC, RV, and FRC after treatment. The
group with a positive exercise response, however, showed a
substantial increase in IC after the Mg infusion. This finding
strongly suggests that improvements in the respiratory
mechanics played an important role in the genesis of
improved exercise performance. This latter result is also
compatible with the concept that progressive respiratory
constraints are central limiting factors for maximal exercise
capacity in COPD, and it highlights the importance of IC
measurements in this setting (33-35).
It is worth noting that the minute ventilation at the peak
of exercise in Group II was significantly higher than that in
Group I. Although this finding might only reflect the higher
level of work load reached, it may also be interpreted as the
true mechanism responsible for an improved exercise
performance. The use of Mg, most likely, was associated
with reductions in dynamic hyperinflation during exercise
in the responders. Unfortunately, measurements of IC
during exercise, which is considered to be a proxy for
dynamic hyperinflation, were not available to completely
confirm this possibility (26).
Table 4 - Effects of Mg loading on the cardiorespiratory parameters of 20 COPD patients at maximal exercise*.
Saline Mg
Treatment Effect (CI 95%)
(Mg-Saline) p-value
HR peak (bpm) 133.3¡12.7 135.6¡13.0 2.3 (-2.8 – 7.4) 0.355
HR peak/HR maxpred. 86.9¡9.0 88.4¡9.0 1.5 (-1.8 – 4.8) 0.353
SBP peak (mmHg) 194.0¡33.2 191.0¡25.4 -2.5 (-9.3 – 4.3) 0.449
DBP peak (mmHg) 103.0¡18.7 99.5¡16.1 -3.5 (-8.8 – 1.8) 0.185
MBP peak (mmHg) 133.3¡22.7 130.2¡17.9 -3.2 (-8.2 – 1.9) 0.205
SaO2 peak (%) 91.1¡3.0 91.6¡3.4 0.5 (-1.0 – 2.0) 0.480
Double product (bpm.mmHg) 25,900¡5,375.7 25,876¡3641.9 (-734.8 – 1,341.5) 0.982
RR peak (bpm) 30.4¡6.7 30.9¡7.5 0.5 (-1,4 – 2,4) 0.593
TV peak (ml) 1,318.4¡314.8 1,408.5¡286.8 90.2 (20.3 – 160.0) 0.014
MV peak (l) 41.1¡15.1 43.6¡15.5 2.5 (-0.3 – 5.3) 0.078
MV peak /MVV (%) 85.4¡19.1 88.9¡21.6 3.5 (-5.1 – 12.0) 0.405
Duration (min, sec) 12942’’ ¡ 3943’’ 13936’’ ¡3919’’ 53’’ (14’’ – 1933’’) 0.011
Maximal load (w) 73.4¡37.8 81.4¡33.7 8.0 (1.5 – 14.4) 0.018
VO2 peak (ml/min) 1,110.6¡342.5 1,110.3¡319.8 8.7 (-54.6 – 72.0) 0.777
VCO2 peak (ml/min) 1,216.8¡433.2 1,288.0¡410.6 71.3 (-27.0 – 169.5) 0.146
RER peak 1.09¡0.13 1.15¡0.19 0.06 (0.01 – 0.11) 0.023
PETO2 peak (mmHg) 98.1¡10.0 98.6¡10.6 0.5 (-0.9 – 1.9) 0.468
PETCO2 peak (mmHg) 39.2¡8.3 38.9¡8.7 -0.4 (-1.6 – 0.9) 0.548
Borg peak dyspnea 6.2¡2.6 6.0¡2.6 -0.2 (-0.91 – 0.51) 0.560
Borg peak leg effort 5.1¡2.8 5.1¡3.0 0.03 (-0.63 – 0.68) 0.937
*HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean arterial blood pressure; SaO2: peripheral arterial oxygen saturation;
RR: respiratory rate; TV: tidal volume; MV: minute ventilation; VO2: oxygen consumption; VCO2: carbon dioxide production;
RER: respiratory exchange rate; PETO2: end tidal expiratory oxygen; PETCO2: end tidal expiratory carbon dioxide.
Table 5 - Comparisons between Mg treatment effects
with COPD patients classified according to the level of
work load response *.
Group I
(n = 10)
Group II
(n = 10) p-value
Plasmatic Mg (mEq/L) 1.5¡0.5 1.5¡0.4 1
TLC (L) -0.46¡1.02 -0.14¡0.82 0.447
FVC (L) -0.03¡0.21 0.10¡0.26 0.209
FEV1 (L) -0.01¡0.17 0.09¡0.12 0.158
FRC (L) -0.43¡1.04 -0.40¡0.72 0.947
RV (L) -0.57¡1.10 -0.37¡0.85 0.647
ERV (L) -0.07¡0.70 -0.03¡0.26 0.894
IC (L) -0.06¡0.29 0.29¡0.32 0.020
HRpeak (bpm) -0.4¡9.7 5.0¡11.7 0.278
MBPpeak (mmHg) 0.0¡10.5 -6.3 10.6 0.197
SaO2 peak (%) 1,3¡3.2 -0.3¡3.2 0.260
MV peak (l) -0.8¡4.5 5.8¡5.6 0.009
Duration (min, sec) -21.8¡20.9 128.1¡45.4 ,0.0001
Maximal load (w) -2.6¡5.8 18.5¡11.0 ,0.0001
VO2 peak (ml/min) -85.4¡89.7 102.8¡104.3 0.0004
VCO2 peak (ml/min) -48.5¡91.5 191.0¡229.8 0.007
RER peak 0.1¡0.1 0.1¡0.1 0.785
Borg peak dyspnea 0.3¡1.2 -0.7¡1.7 0.142
Borg peak leg effort 0.4¡1.0 -0.3 1.7 0.312
*Group I: Changes in work load ,5 w; Group II; Changes in work load
$5 w. TLC: total lung capacity; FVC: forced vital capacity; FEV1: forced
expiratory volume in the first second; FRC: functional respiratory
capacity; RV: residual volume; ERV: expiratory reserve volume;
IC: inspiratory capacity; HR: heart rate; MBP: mean blood pressure; SaO2:
peripheral arterial oxygen saturation; MV: minute ventilation;
VO2: oxygen consumption; VCO2: carbon dioxide production; RER:
respiratory exchange rate.
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The overall set of results indicates that the improvement
in exercise performance that is associated with the Mg
treatment does not appear to be secondary to changes in the
heart function.
An additional potential contributing mechanism to the
present findings is that the Mg treatment led to a higher
efficacy of the exercise mechanism itself. The acute loading
of Mg may have influenced the muscle contraction or the
peripheral energy production process in this setting. Animal
studies have shown that Mg administration leads to
increases in the glucose available to tissues, decreases in
lactate release and increases in pyruvate production (36-39).
In addition, Mg oral supplementation in athletes has been
shown to increase glucose blood levels during exercise via
ACTH and cortisol discharge (39). Most importantly,
because Mg is a cofactor that binds to ATP molecules,
increases in intracellular Mg may also improve ATP
production and glucose utilization (40). It has also been
suggested that Mg supplementation may enhance the
endothelial function by increasing the local NO availability,
decreasing platelet aggregation, and reducing oxidative
stress (41,42).
Although the VO2 and VCO2 of the overall group of
patients did not differ between treatments, the RER showed
a small but significant increase after the Mg infusion (0.06;
p= 0.023). This finding could be better explained by a
change in the metabolic profile, with an Mg-induced rise in
glucose utilization, as previously suggested.
The present study has several limitations, including the
small number of patients enrolled, the lack of a standard
inquiry for dietary Mg ingestion, the lack of an adequate
measurement of exercise dynamic hyperinflation, and the
need for biochemical determinations during exercise.
Dynamic inspiratory capacity evaluations and biochemical
measurements, such as blood lactate and glucose levels,
would permit less speculative explanations for the observed
improvements in exercise performance. As Mg has sub-
stantial metabolic actions, it would be more informative
if the present study had also measured intracellular Mg
concentrations. In addition, technical problems did not
permit the determination of the aerobic threshold in eight
COPD patients, which precluded an adequate analysis of
the data related to this parameter in the group.
The effects of Mg on peak exercise, although statistically
significant, were small, with a mean load addition of 8 w.
The clinical meaning of this finding is presently unknown,
but it appears that it should be of little relevance.
Additionally, this level of improvement was obtained with
mean Mg plasma levels of approximately 3 mEq/L, which
are substantially higher than in the typical physiological
range (1.5–2.5 MEq/L). On the other hand, intracellular Mg
levels may be more important than plasma measurements.
Certainly, definitive answers to the questions generated by
this paper will only be possible after clinical trials involving
the oral supplementation of Mg in COPD patients for longer
periods.
The acute IV loading of 2 g of Mg was associated with a
reduction in static hyperinflation and increases in the load
reached with incremental maximal exercise tests. Post-hoc
analyses indicated that the positive exercise response was
due to improvements in respiratory mechanics. The present
results suggest that higher circulating levels of Mg may be
beneficial for COPD patients. These findings also indicate
the need for further studies investigating the effects of
chronic dietary supplementation with Mg on the pulmonary
function parameters and exercise tolerance of stable COPD
patients.
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